DOCSLIB.ORG

Martindale 38 Brochure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Martindale 38 Brochure Edition 38 TH The NEW Martindale NEW The INTERNATIONAL OBJECTIVE & UNBIASED & OBJECTIVE WIDE REACHING WIDE AUTHORITATIVE Since its very first edition, Martindale: The Complete Drug Reference has been relied upon by pharmacists for information on drugs and medicines. Now, this completely revised and updated 38 the breadth and volume of content onTH edition offer in once a single again resource. sets a new standard for What makes the 38 TH edition so special? • The new Martindale has been redesigned to make it easier to access information, with greater emphasis on uses and administration. So, when you have a query, you’ll get to the right answer quickly. • The content has been expanded, with over 200 new monographs and increased global coverage of proprietary preparations. • Underpinning Martindale is the same stringent, independent and objective editorial process that has made Martindale indispensable to pharmacists across the globe. • The 38TH edition contains : - Over 6,000 drug monographs including over 200 new to this edition - Information on over 180,000 drug preparations - Over 54,000 reference citations - Details of almost 20,000 drug manufacturers and distributors - Information on proprietary drug preparations from 43 countries and regions • As well as drugs and medicines, Martindale includes over 700 disease reviews and information on herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins and poisons. Amlexanox/Caffeine 1203 duration of action of bambuterol of at least 24 hours. Preparations Bambuterol Hydrochloride Hydrolysis of bambuterol is catalysed by plasma cholin- ..................................................................................................... (BANM, rINNM) : esterase; however, bambuterol also inhibits plasma cholin- Proprietary Preparations (details are given in Volume B) Bambutérol, Chlorhydrate de; Bambuterol, hidrocloruro de; esterase and therefore partly inhibits its own metabolism. Single-ingredient Preparations. USA: Tornalate†. Bambuterol-hidroklorid; Bambuterolhydrochlorid; Bambu- For the metabolism and excretion of terbutaline, see terol-hydrochlorid; Bambuterolhydroklorid; Bambuteroli p. 1229.1. hydrochloridum; Bambuterolihydrokloridi; Bambuterolio References. Bufylline (BAN) hidrochloridas; Hidrocloruro de bambuterol; KWD-2183; 1. Sitar DS. Clinical pharmacokinetics of bambuterol. Clin Pharmacokinet 1996; 31: 246–56. Ambuphylline (USAN); Bufilina; Theophylline-aminoisobuta- Бамбутерола Гидрохлорид. 2. Nyberg L, et al. Pharmacokinetics of bambuterol in healthy subjects. Br J nol; Буфиллин. (RS)-5-(2-tert-Butylamino-1-hydroxyethyl)-m-phenylene bis Clin Pharmacol 1998; 45: 471–8. 2-Amino-2-methylpropan-1-ol theophyllinate. (dimethylcarbamate) hydrochloride. 3. Bang U, et al. Pharmacokinetics of bambuterol in subjects homozygous C H N O =269.3 for the atypical gene for plasma cholinesterase. Br J Clin Pharmacol 1998; 11 19 5 3 C18H29N3O5,HCl=403.9 45: 479–84. CAS — 5634-34-4. CAS — 81732-65-2 (bambuterol); 81732-46-9 (bambuterol 4. Ahlstro¨ m H, et al. Pharmacokinetics of bambuterol during oral ATC — R03DA10. monohydrochloride). administration to asthmatic children. Br J Clin Pharmacol 1999; 48: 299– ATC Vet — QR03DA10. The new layout and 308. Drug ATC — R03CC12. 5. Rosenborg J, et al. Pharmacokinetics of bambuterol during oral UNII — VOU5V0B772. ATC Vet — QR03CC12. administration of plain tablets and solution to healthy adults. Br J Clin Pharmacol 2000; 49: 199–206. design of Martindale UNII — 786Q84QZ3F. Profile nomenclature ..................................................................................................... Pharmacopoeias. In Eur. (see p. vii). Preparations Bufylline is a theophylline derivative (p. 1229.3) that has ..................................................................................................... TH Ph. Eur. 8: (Bambuterol Hydrochloride). A white or almost been used for its bronchodilator effects as an ingredient of highlighted for white crystalline powder. It exhibits polymorphism. Freely Proprietary Preparations (details are given in Volume B) 38 edition make preparations promoted for coughs and other respiratory- soluble in water; soluble in alcohol. Single-ingredient Preparations. Austria: Bambec; Braz.: Bam- tract disorders. The ethiodide has also been used. bair; Bambec; China: Ao Duo Li (奥多利); Bambec (帮备); clarity Uses and Administration BangShun (邦顺); Bei He Jian (贝合健); Hui Jie (汇杰); Li Ke Preparations it even easier for ..................................................................................................... ..................................................................................................... Fei (立可菲); Luo Xi (洛希); LuoLi (罗利); Zhu Long (祝龙); Bambuterol is an inactive prodrug of terbutaline Denm.: Bambec; Oxeol; Fr.: Oxeol; Ger.: Bambec; India: Abel; Proprietary Preparations (details are given in Volume B) (p. 1228.1), a direct-acting sympathomimetic with mainly Asthafree; Bambudil; Bemlo; Betaday; Norw.: Bambec; NZ: Multi-ingredient Preparations. Braz.: EMS Expectorante; Revenil you to find the beta-adrenergic activity and a selective action on beta2 Bambec; Philipp.: Bambec; Bambutec; Pulmitac; Singapore: Dospan; Revenil Expectorante; Revenil; Xpe Expectorante; S. receptors (a beta2 agonist). It has similar actions to those of Bambec; Spain: Bambec; Swed.: Bambec; Thai.: Bambec; UK: Afr.: Nethaprin Dospan†; Nethaprin Expectorant†. salbutamol (p. 1220.2) except that it has a more prolonged Bambec. duration of action (at least 24 hours). Bambuterol reliable, unbiased hydrochloride is used as a long-acting bronchodilator for Multi-ingredient Preparations. India: Montair Plus; Monway persistent reversible airways obstruction in conditions such Plus; Odimont Plus. Caffeine (BAN) as asthma (p. 1195.2). The usual dose is 10 to 20 mg orally Anhydrous Caffeine; Cafeína; Cafeína anhidra; Caféine; New typography drugs and medicines once daily at bedtime. Doses may need to be reduced in Coffein; Coffeinum; Guaranina; Guaranine; Kofeiini; Kofein; renal impairment (see below). Bamifylline Hydrochloride Kofeina; Kofeinas; Koffein; Methyltheobromine; Metilteobro- makes Martindale Uses and (BANM, USAN, rINNM) mina; Teína; Théine; Кофеин. Administration in renal impairment. Licensed product 1,3,7-Trimethylpurine-2,6(3H,1H)-dione; 1,3,7-Trimethyl- information you information recommends that the initial dose of bambu- AC-3810; Bamifilina, hidrocloruro de; Bamifylline, Chlorhy- xanthine; 7-Methyltheophylline. easier to use Administration terol hydrochloride should be halved in patients with drate de; Bamifyllini Hydrochloridum; BAX-2739Z; 8102-CB; renal impairment (glomerular filtration rate less than CB-8102; Hidrocloruro de bamifilina; Бамифиллина C8H10N4O2=194.2 need and can depend 50 mL/minute). Further doses should be adjusted accord- Гидрохлорид. CAS — 58-08-2. now located at ing to response. 8-Benzyl-7-[2-(N-ethyl-N-2-hydroxyethylamino)ethyl]theo- ATC — N06BC01. phylline hydrochloride. ATC Vet — QN06BC01. Asthma. References. C20H27N5O3,HCl=421.9 UNII — 3G6A5W338E. upon. It is published 1. Fugleholm AM, et al. Therapeutic equivalence between bambuterol, the start of each CAS — 2016-63-9 (bamifylline); 20684-06-4 (bamifylline NOTE. Compounded preparations of caffeine may be 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma. Eur Respir J 1993; 6: 1474–8. hydrochloride). represented by the following names: 2. Gunn SD, et al. Comparison of the efficacy, tolerability and patient ATC — R03DA08. Co-bucafAPAP (PEN)—butalbital, paracetamol, and in print as a practical, monograph acceptability of once-daily bambuterol tablets against twice-daily ATC Vet — QR03DA08. caffeine. controlled release salbutamol in nocturnal asthma. Eur J Clin Pharmacol 1995; 48: 23–8. UNII — 66466QLM3S. Pharmacopoeias. In Eur. (see p. vii), Int., Jpn, US, and Viet. 3. Zarkovic JP, et al. The Bambuterol Multicentre Study Group. One-year Some pharmacopoeias include caffeine and caffeine hydrate Clearer text two-volume set. safety study with bambuterol once daily and terbutaline three times under one monograph. daily in 2-12-year-old children with asthma. Pediatr Pulmonol 2000; 29: Profile 424–9. ..................................................................................................... Ph. Eur. 8: (Caffeine). A white or almost white, crystalline Bamifylline hydrochloride is a theophylline derivative powder or silky white or almost white crystals. It sublimes structure makes Adverse Effects and Precautions (p. 1229.3) that is used for its bronchodilator properties in readily. Sparingly soluble in water; freely soluble in boiling ..................................................................................................... reversible airways obstruction. It is not converted to water; slightly soluble in dehydrated alcohol. It dissolves in As for Salbutamol, p. 1221.3. Bambuterol is not theophylline in the body. It is given in usual oral doses of concentrated solutions of alkali benzoates or salicylates. each entry easier recommended for patients with severe hepatic impairment 600 or 900 mg daily in 2 or 3 divided doses. It is also given USP 36: (Caffeine). It is anhydrous or contains one as its metabolism would be unpredictable. The dose of rectally as suppositories, and by slow intravenous infusion. molecule of water of hydration. An odourless white powder bambuterol should be reduced in renal impairment (see to find or white, glistening needles, usually
Load more

Recommended publications
  • Dosing Time Matters
    bioRxiv preprint doi: https://doi.org/10.1101/570119; this version posted March 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dosing Time Matters 1 2,3 4,5,6 1* Marc D. Ruben ,​ David F. Smith ,​ Garret A. FitzGerald ,​ and John B. Hogenesch ​ ​ ​ ​ 1 Division​ of Human Genetics, Center for Chronobiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 240 Albert Sabin Way, Cincinnati, OH, 45229 2 Divisions​ of Pediatric Otolaryngology and Pulmonary and Sleep Medicine, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229 3 Department​ of Otolaryngology-Head and Neck Surgery, University of Cincinnati School of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267 4 Department​ of Systems Pharmacology and Translational Therapeutics, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 5 Department​ of Medicine, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 6 ​ Institute for Translational Medicine and Therapeutics (ITMAT), at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA *Corresponding Author. Email: [email protected] Abstract Trainees in medicine are taught to diagnose and administer treatment as needed; time-of-day is rarely considered. Yet accumulating evidence shows that ~half of human genes and physiologic functions follow daily rhythms. Circadian medicine aims to incorporate knowledge of these rhythms to enhance diagnosis and treatment.
    [Show full text]
  • Spirometry Protocol and Software Training Handout
    SPIROMETRY PROTOCOL AND SOFTWARE TRAINING HANDOUT Spirometry Protocol Key Points in Performing Spirometry ▪ Always demonstrate the maneuver ▪ Prompt the participant to BLAST out the air ▪ Continue by having the participant PUSH out the air ▪ Continue until the balloon bursts or at least six seconds Getting ready to do Spirometry Subjects will be instructed to not use any bronchodilator medicines for at least 4 hours prior to the appointment (in the case of salmeterol [Serevent] or Fomoterol (foradil)or Tritoprium (Spiriva) avoid for 12 hours prior to the test). Bronchodilator medicines include: Short acting bronchodilators Albuterol (ventolin, proventil, airet, volmax tablet) Levalbuterol (xopenex) Metaproterenol (alupent) Pirbuterol (maxair) Terbutaline (brethaire, brethine, bricanyl) Isoetharine (bronkosol) Ipratropium (atrovent) Ipratropium and albuterol combination (Combivent) Isoproteranol (isuprel) Primatine 1 CHW Educational Protocols – Spirometry Protocol and Software Training Handout Bitolterol (tornalate) Long acting bronchodilator Salmeterol (serevent) Fomoterol (foradil) Tritoprium (Spiriva) Bronchodilators should be avoided because they can affect the spirometry results. If the patient is having symptoms from asthma and needs to use the medicine, ask that the medicine be used 4 hours before the visit, so that the next dose is due during the visit. Patients can then do the spirometry and then the patient can take the medicine after the test is completed. When scheduling the follow-up spirometry visit, if at all possible, try to make the visit at the same time as the initial baseline visit. 1. Preparing the Computer 1. Check to see if the time and date on the lower right hand corner is current. If the date and time is NOT, the spirometer will NOT sync with the computer or the Easy One software.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • CBCS SYLLABUS) SUBJECT-BPH C 801 T-Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK
    FINAL YEAR UNIVERSITY EXAMINATION 2019-2020 Final Year B.Pharm. Semester VIII (CBCS SYLLABUS) SUBJECT-BPH_C_801_T-Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK SET-I Q. 1 Which is the correct IUPAC name for the following structure? A] 5-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine B] 7-chloro-2-(methylamino)-5-pyridinyl-3H-1,4-benzodiazepine-4-oxide C] 7-chloro-2-(ethylamino)-5-phenyl-3H-1,5-benzodiazepine D] 7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine-4-oxide Q. 2 Which of the following is long acting sedative hypnotic? A] Diazepam B] Alprazolam C] Temazepam D] Imipramine Q. 3 Name of oxide derivative used as sedative hypnotic is A] Diazepam B] Chlordiazepoxide C]Nitazepam D] Ramelteon Q. 4 With respect to the following general structure which is the correctstatement ? A] X must be electropositive substituent for optimum activity B] X must be aromatic ring for optimum activity C] X must be electronegative substituent for optimum activity D] X must be H for optimum activity Q. 5 Which is the incorrect statement with respect to structure given in Q. 4 A] Ring C is ortho substituted with electron withdrawing group for optimum activity B] Ring C when para substituted increases activity C] Ring C is diortho substituted with electron withdrawing group for optimum activity D] Ring C when para substituted decreases activity Q. 6 What is the starting material for synthesis of Piroxicam (structure given below) A] B] C] D] Q. 7 Which one of the following is Cytokine inhibitor? A] Abatacept B] Fluoxetine C] Propranolol D]Aldosterone Q.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • COVID-19 Evidence Bulletin 8
    COVID-19 Evidence Bulletin 8 Public Health England PHE International Epidemiology Daily Evidence Digest – 22nd April 2020 – 21st April 2020 – 20th April 2020 NICE COVID-19 rapid guideline: acute myocardial injury [NG171] Published 23rd April The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response [NG172] Published 23rd April The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community Published 3rd April, Last updated 22nd April NHS England Specialty Guides: Clinical guide for acute kidney injury in hospitalised patients with COVID-19 outside the intensive care unit during the coronavirus pandemic (22nd April - updated) Management of palliative care in hospital during the coronavirus pandemic (22nd April – updated) Department of Health and Social Care Medicines that cannot be parallel exported from the UK (22nd April) 33 medicines have been added to the parallel export list and the
    [Show full text]
  • Amlexanox TBK1 & Ikke Inhibitor Catalog # Inh-Amx
    Amlexanox TBK1 & IKKe inhibitor Catalog # inh-amx For research use only Version # 15I29-MM PRODUCT INFORMATION METHODS Contents: Preparation of 10 mg/ml (33.5 mM) stock solution • 50 mg Amlexanox 1- Weigh 10 mg of Amlexanox Storage and stability: 2- Add 1 ml of DMSO to 10 mg Amlexanox. Mix by vortexing. - Amlexanox is provided lyophilized and shipped at room temperature. 3- Prepare further dilutions using endotoxin-free water. Store at -20 °C. Lyophilized Amlexanox is stable for at least 2 years when properly stored. Working concentration: 1-300 μg/ml for cell culture assays - Upon resuspension, prepare aliquots of Amlexanox and store at -20 °C. Resuspended Amlexanox is stable for 6 months when properly stored. TBK1/IKKe inhibition: Quality control: Amlexanox can be used to assess the role of TBK1/IKKe using cellular - Purity ≥97% (UHPLC) assays, as described below in B16-Blue™ ISG cells. - The inhibitory activity of this product has been validated using cellular 1- Prepare a B16-Blue™ ISG cell suspension at ~500,000 cells/ml. assays. 2- Add 160 µl of cell suspension (~75,000 cells) per well. - The absence of bacterial contamination (e.g. lipoproteins and 3- Add 20 µl of Amlexanox 30-300 µg/ml (final concentration) and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ incubate at 37 °C for 1 hour. TLR4 cells. 4-Add 20 µl of sample per well of a flat-bottom 96-well plate. Note: We recommend using a positive control such as 5’ppp-dsRNA delivered intracellularly with LyoVec™ . DESCRIPTION 5- Incubate the plate at 37 °C in a 5% CO incubator for 18-24 hours.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • TR-473: Theophylline (CASRN 58-55-9) in F344/N Rats And
    NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF THEOPHYLLINE (CAS NO. 58-55-9) IN F344/N RATS AND B6C3F1 MICE (FEED AND GAVAGE STUDIES) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 August 1998 NTP TR 473 NIH Publication No. 98-3963 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals.
    [Show full text]
  • Fatty Liver Disease (Nafld/Nash)
    CAYMANCURRENTS ISSUE 31 | WINTER 2019 FATTY LIVER DISEASE (NAFLD/NASH) Targeting Insulin Resistance for the Metabolic Homeostasis Targets Treatment of NASH Page 6 Page 1 Special Feature Inside: Tools to Study NAFLD/NASH A guide to PPAR function and structure Page 3 Pathophysiology of NAFLD Infographic Oxidative Stress, Inflammation, and Apoptosis Targets Page 5 Page 11 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · (800) 364-9897 · WWW.CAYMANCHEM.COM Targeting Insulin Resistance for the Treatment of NASH Kyle S. McCommis, Ph.D. Washington University School of Medicine, St. Louis, MO The obesity epidemic has resulted in a dramatic escalation Defects in fat secretion do not appear to be a driver of in the number of individuals with hepatic fat accumulation hepatic steatosis, as NAFLD subjects display greater VLDL or steatosis. When not combined with excessive alcohol secretion both basally and after “suppression” by insulin.5 consumption, the broad term for this spectrum of disease Fatty acid β-oxidation is decreased in animal models and is referred to as non-alcoholic fatty liver disease (NAFLD). humans with NAFLD/NASH.6-8 A significant proportion of individuals with simple steatosis will progress to the severe form of the disease known as ↑ Hyperinsulinemia Insulin resistance non-alcoholic steatohepatitis (NASH), involving hepatocyte Hyperglycemia damage, inflammation, and fibrosis. If left untreated, Adipose lipolysis NASH can lead to more severe forms of liver disease such Steatosis as cirrhosis, hepatocellular carcinoma, liver failure, and De novo O ↑ lipogenesis HO eventually necessitate liver transplantation. Due to this large clinical burden, research efforts have greatly expanded Fatty acids to better understand NAFLD pathogenesis and the mechanisms underlying the transition to NASH.
    [Show full text]
  • Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F
    PROGRESS IN GERIATRICS Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F. Donegan, MD, Allan Moore, MD, and Noel Gerard McElvaney, MD Despite comprehensive guidelines established by the Euro- from 6.5% to 17.0%.5 Death rates associated with asthma pean Global Initiative for Asthma and the U.S. National depend on patient age; in a group of patients aged 55 to 59, Asthma Education and Prevention Program on the diagno- the death rate was 2.8 per 100,000 people, whereas in sis and management of asthma, its mortality in older adults people aged 60 to 64, it was 4.2 per 100, 000.6 Diagnostic continues to rise. Diagnostic and therapeutic problems and therapeutic problems contribute to many patients being contribute to older patients being inadequately treated. The inadequately treated. Despite its importance in older pa- diagnosis of asthma rests on the history and characteristic tients, asthma is particularly difficult to diagnose in this age pulmonary function testing (PFT) with the demonstration group. Symptoms typical of asthma such as intermittent of reversible airway obstruction, but there are unique prob- wheezing, breathlessness, and cough can also indicate other lems in performing this test in older patients and in its in- respiratory problems in older patients, particularly chronic terpretation. This review aims to address the difficulties in obstructive pulmonary disease (COPD). Similarly, other performing and interpreting PFT in older patients because symptoms of asthma such as chest pain or tightness may of the effects of age-related changes in lung function on be due to nonpulmonary disease such as ischemic heart respiratory physiology.
    [Show full text]